Shenqi Yishen Granules
DrugA traditional Chinese medicine compound for the treatment of IgA nephropathy
Other names: Irbesartan
NCT Number: NCT07360002
The goal of this clinical trial is to learn if Shenqi Yishen Granules works to treat IgA Nephropathy in adults. It will also learn about the safety of Shenqi Yishen Granules. The main questions it aims to answer are:
Does Shenqi Yishen Granules lower 24-hour urinary protein quantification of participants? What medical problems do participants have when taking Shenqi Yishen Granules? Researchers will compare Shenqi Yishen Granules to a placebo (a look-alike substance that contains no drug) to see if Shenqi Yishen Granules works to treat IgA Nephropathy.
Trial opening soon.
Get Notified18 year–75 year
All sexes
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A traditional Chinese medicine compound for the treatment of IgA nephropathy
Other names: Irbesartan
a look-alike substance that contains no drug
Other names: Irbesartan
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
24-hour urinary protein quantification
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Concentration of Protein-to-creatinine rati
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Red blood cells in urine
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Glomerular filtration rate
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
The number of infections in the respiratory, gastrointestinal, or urinary tract
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Assess the patient's clinical symptoms based on the rating scale; the higher the score, the more severe the symptoms.
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Safety indicators
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Determine whether the patient has experienced adverse cardiac events based on the electrocardiogram
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Safety indicators
Time frame: 0 weeks, 4 weeks, 8 weeks, 12 weeks
Security indicators
Time frame: 0 weeks, 4weeks, 8 weeks, 12 weeks
Security indicators
Keda Lu
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07649538
Autoimmune Diseases, Female Urogenital Diseases
Leicester, United Kingdom
View Trial DetailsNCT07604311
Autoimmune Diseases, Female Urogenital Diseases
View Trial DetailsNCT07555301
Autoimmune Diseases, Female Urogenital Diseases
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT07553494
Autoimmune Diseases, Female Urogenital Diseases
Beijing, Beijing Municipality, China
View Trial Details